{"id":"fec-doc-adjuvant-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Peripheral neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FEC (fluorouracil, epirubicin, cyclophosphamide) is a standard anthracycline-based chemotherapy combination that damages DNA in cancer cells. Docetaxel (Doc), a taxane, is added sequentially to further inhibit microtubule function and enhance cytotoxic effects. This adjuvant approach targets residual micrometastatic disease after surgery to improve disease-free and overall survival.","oneSentence":"FEC-Doc is a combination chemotherapy regimen that uses fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel to kill rapidly dividing cancer cells and prevent recurrence.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:29.744Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of early-stage breast cancer (Phase 3 trial context)"}]},"trialDetails":[{"nctId":"NCT02181101","phase":"PHASE3","title":"Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2005-09","conditions":"Breast Neoplasms","enrollment":3754},{"nctId":"NCT00047099","phase":"PHASE3","title":"Combination Chemotherapy in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2001-08","conditions":"Breast Cancer","enrollment":446},{"nctId":"NCT00670878","phase":"PHASE3","title":"Studying the Benefits of Adjuvant Sequential vs. Combined Taxane Based Chemotherapy, Followed by Different Biological Treatment Strategies in Early, HER2-positive Breast Cancer","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2008-06","conditions":"Breast Cancer","enrollment":799}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"FEC-Doc adjuvant chemotherapy","genericName":"FEC-Doc adjuvant chemotherapy","companyName":"Ludwig-Maximilians - University of Munich","companyId":"ludwig-maximilians-university-of-munich","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FEC-Doc is a combination chemotherapy regimen that uses fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel to kill rapidly dividing cancer cells and prevent recurrence. Used for Adjuvant treatment of early-stage breast cancer (Phase 3 trial context).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}